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Adenosine is an endogenously produced compound that has 
significant effects as a coronary and systemic vasodilator. Previous 
studies suggest that intravenous infusion of adenosine, coupled 
with thallium-201 scintigraphy, may have specific value as a 
noninvasive means of evaluating coronary artery disease. The 
purpose of this study was to compare the diagnostic value of 
adenosine thallium testing with that of standard exercise thallium 
testing. 
One hundred subjects were studied with exercise thallium 
imaging and thallium imaging after adenosine infusion, including 
47 with angiographically proved coronary artery disease and 53 
control subjects. The overall sensitivity of the thallium procedures 
was 81 % for the exercise study and 83% for the adenosine study 
(p = NS); the specificity was 74% for the exercise study and 75% 
Adenosine is an endogenously produced compound with 
potent cardiovascular effects. The most significant effect of 
the nucleoside appears to be related to its systemic and 
coronary vasodilator properties (1-3). Adenosine's ability to 
augment coronary flow has been demonstrated by intracor-
onary Doppler flow velocity measurements (4), and its 
systemic effects have been used to control blood pressure 
during cerebrovascular (5) and pheochromocytoma surgery 
(6). 
Because of its ability to produce coronary vasodilation 
similar to that seen with dipyridamole, intravenous admin-
istration of exogenous adenosine in conjunction with thal-
lium-2ot scintigraphy has been suggested to have specific 
value in the diagnosis of fixed, obstructive, epicardial coro-
nary disease (7,8). The very brief half-life of adenosine. 
about 10 s, may make it particularly suitable for use as a 
short-acting vasodilator (9). In previous studies, a short 
half-life was associated with a favorable side effect profile. 
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for the adenosine study (p = NS). The diagnostic accuracy of the 
exercise study was 77 % and that of the adenosine study was 79 % . 
Ninety-four percent of subjects had an adverse effect due to the 
adenosine infusion; however, most of these effects were mild and 
well tolerated. All adverse effects abated within 30 to 45 s of the 
termination of the study, consistent with the very brief half-life of 
the agent. 
Thus, thallium-201 scintigraphy after intravenous infusion of 
adenosine has a diagnostic value similar to that of exercise 
thallium testing for evaluation of coronary artery disease. Aden-
osine thallium testing may be particularly useful in evaluating 
patients unable to perform treadmill exercise testing. 
(J Am Coll CardioI1991;17:1289-94) 
In the current study we compared the diagnostic value of 
thallium-201 imaging after intravenous infusion of adenosine 
with the diagnostic value of thallium-2ot imaging after tread-
mill exercise testing for evaluation of coronary artery dis-
ease. 
Methods 
Study patients. We studied 100 subjects, 47 with angio-
graphically proved coronary disease and 53 with either 
normal coronary arteries at cardiac catheterization (8 sub-
jects) or a <5% probability of having coronary disease as 
determined by stepwise probability analysis (10) based upon 
age, gender, symptoms and results of exercise electrocar-
diography (45 subjects). Patients with unstable angina, re-
cent myocardial infarction (within 1 week), known left main 
coronary artery disease, uncontrolled arrhythmias, New 
York Heart Association class IV congestive heart failure, 
greater than first degree heart block without a permanent 
pacemaker, or a history of bronchospastic lung disease were 
excluded from the study. Patients were identified for recruit-
ment into the study after having undergone a standard 
exercise thallium study or cardiac catheterization, or both. 
Patients who underwent cardiac catheterization from Febru-
ary 1989 through December 1989 who did not meet the 
exclusion criteria and were willing to provide informed 
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consent were recruited for participation in the protocol. 
Normal volunteers were recruited largely from hospital 
personnel. 
The study protocol was approved by the Institutional 
Review Board of Wilford Hall USAF Medical Center. Sub-
jects used in this research gave fully informed consent as 
required by U.S. Air Force regulation. 
Exercise thallium testing. Each subject underwent a 
symptom-limited exercise thallium test using either the mod-
ified or standard Bruce protocol. Electrocardiographic 
(ECG) criteria for an abnormal test result were :::: I mm 
horizontal ST segment depression in more than one lead or 
:::: 1.5 mm upsloping depression 0.08 s after the J point in 
more than one lead. A bolus of approximately 3.5 mCi of 
thallium-201 was injected intravenously I min before the end 
of exercise. Single photon emission computed tomography 
(SPECT) scanning was begun within 5 min of exercise 
termination. Repeat scanning was performed 3 to 5 h later. 
Imaging was done with a low energy, all purpose colli-
mator on an ARC 3000 camera and ADAC computer system. 
The photopeak was set at 76 keY with a 15% window. 
SPECT images were acquired over a 180° arc from 45° left 
posterior oblique to 45° right anterior oblique. The computer 
was set for a 32 frame acquisition at 40 s per frame with a 64 
x 64 x 8 matrix. Sinograms were obtained on each acquisi-
tion to assess patient movement. Processing was performed 
by using standard ADAC protocols. Midventricular short-
axis slices had an immediate postexercise average back-
ground-corrected count density of 10,520 for patients and 
13,675 for control subjects. Adenosine infusion resulted in 
an average background-corrected count density of 15,870 for 
patients and 14,030 for control subjects. 
Adenosine thallium testing. All medicines except for 
theophylline preparations and dipyridamole were continued 
on a routine schedule at the time of adenosine testing. Two 
intravenous lines were inserted, one of which was placed in 
an antecubital vein. Adenosine (Adenoscan, Medco Re-
search, Inc.) was administered through the more proximal of 
the two intravenous lines at a rate of 140 p,g/kg per min. The 
infusion was maintained for 6 min with continuous ECG 
monitoring. Blood pressure and a 12 lead ECG were re-
corded at I min intervals. Three minutes after the start of the 
infusion, approximately 3.5 mCi of thallium-201 was admin-
istered through the second intravenous line. SPECT imaging 
was initiated within 5 min of the end of drug infusion and 
performed in a manner identical to that used in the exercise 
study. The same camera was used to image both exercise 
and adenosine studies for each patient. 
Tomograms were reconstructed in the short axis and 
vertical long axis. The resultant myocardial images were 
divided into anterior, septal, inferior, lateral and apical 
segments. Initial defects were noted for each segment and 
considered abnormal only if present in two or more contig-
uous tomographic slices. Reversibility at 4 h redistribution 
imaging was determined visually. Thallium images were 
interpreted visually by two sets of independent observers 
Table 1. Medications 
Patients 
(n = 47) 
Nitrates 30 (63.8%) 
Calcium channel blockers 29 (61.7%) 
Beta blockers 21 (44.7%) 
ACE inhibitors 9 (19.1%) 
Diuretics 7 (14.9%) 
Digoxin 4 (8.5%) 
Combination therapy 32 (68.1%) 
ACE = angiotensin-converting enzyme. 
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Control Subjects (n = 53) 
Low Likelihood Normal 
of Coronary Coronary 
Disease Arteries 
(n = 45) (n = 8) 
0 3 (37.5%) 
0 2 (25%) 
0 2 (25%) 
0 2 (25%) 
1 (2.2%) 3 (37.5%) 
0 2 (25%) 
0 4 (50%) 
who had no knowledge of patient identification or the results 
of coronary angiography and prior thallium testing. Differ-
ences in interpretation were settled by consensus. The two 
thallium studies were performed 7 to 10 days apart and 
within 30 days of cardiac catheterization. 
Coronary angiography. Cardiac catheterization films 
were interpreted by a senior angiographer who did not know 
the results of the thallium tests. Significant coronary disease 
was defined as ::::50% diameter reduction by caliper measure-
ment in one or more major epicardial vessel. 
Statistical methods. The chi-square or Fisher exact test 
was used as appropriate, depending on sample size to 
compare the frequencies of normal and abnormal tests 
between groups. Differences were considered significant at a 
p value <0.05. McNemar's test of symmetry and the kappa 
measure of reliability were used to determine the agreement 
between the exercise and adenosine thallium examinations 
and any advantage of one test over the other. Continuous 
variables were compared by using a two-tailed t test for 
paired or unpaired data. Operating characteristics of the 
thallium tests were determined by calculating sensitivity, 
specificity, positive predictive value, negative predictive 
value and test accuracy according to standard formulas. 
"Normalcy" rates for the two tests were determined as the 
percent of normal results in subjects with a low likelihood of 
disease who did not undergo catheterization. 
Results 
Patient characteristics (Table 1). The study group con-
sisted of 47 patients and 53 normal control subjects. The 
average age of the normal group was 35.4 ± 11.2 years and 
75.5% were men. The average age of the patient group was 
59.6 ± 10.4 years and 83% were men. No patient experi-
enced a clinical event (e.g.; myocardial infarction or devel-
opment of unstable symptoms) or underwent revasculariza-
tion between the two studies. Prescribed cardiovascular 
medications at the time of adenosine study are listed in 
Table I. 
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Table 2. Thallium Image Interpretation in 100 Subjects 
Exercise Adenosine 
Thallium Thallium 
Test Test 
True negative 39 40 
False positive 14 13 
True positive 38 39 
False negative 9 8 
Sensitivity 0.81 0.83* 
Specificity 0.74 0.75* 
Normalcy rate 0.80 0.80* 
Positive predictive value 0.73 0.75* 
Negative predictive 0.81 0.83* 
value 
*p = NS compared with exercise study. 
Results of SPECT thallium imaging (Table 2). Fixed and 
reversible perfusion defects are grouped together and termed 
abnormal. The overall sensitivity of exercise thallium testing 
for coronary artery disease was 81% and that of adenosine 
thallium testing was 83%. These levels of sensitivity were 
not significantly different (p = 0.79). The specificity of 
exercise thallium testing was 74% and that of ade~osine 
thallium testing was 75%. In the 45 sl!bjects with a low 
clinical probability of coronary disease who did not undergo 
cardiac catheterization, the normalcy rate of both tests was 
80%. The positive predictive value of exercise thallium 
testing was 73% and that of adenosine thallium testing was 
75%. The negative predictive values of exercise and adeno-
sine thallium testing were 81% and 83%, respectively. The 
diagnostic accuracy of the exercise and adenosine thallium 
tests was 77% and 79%, respectively. There were no signif-
icant differences between exercise and adenosine thallium 
imaging for any of the calculated test characteristics. A 
kappa value of 0.60 indicated good agreement between the 
results of the two tests. 
The sensitivity of exercise and adenosine thallium testing 
was calculated in the group of patients who did not have 
evidence of previous transmural myocardial infarction by 
left ventriculography. This group consisted of 28 persons 
with either normal wall motion or hypo kinetic left ventricu-
lar segments. Patients with akinetic or dyskinetic segments 
were excluded. In this group, the sensitivity of exercise 
thallium testing was 75% and that of adenosine thallium 
testing was 79% (p = NS). 
Electrocardiographic results (Table 3). Twelve of the 47 
patients had an abnormal ECG response to exercise testing, 
whereas only 2 of these 47 had an abnormal ECG response to 
adenosine. The difference in frequency of abnormal ECG 
responses to the two tests was statistically significant. Ab-
normal ECG responses to exercise were more common in 
patients than in control subjects (12 of 47 versus 2 of 53, p < 
0.001) but not with adenosine infusion (2 of 47 versus 1 of 53, 
p = NS). 
.Chest pain response (Table 4). During exercise, chest 
pam was more common in patients than in normal subjects 
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Table 3. Electrocardiographic Results in Patients and 
Control Subjects 
Normal 
Nonspecific 
Abnormal 
Patients (n = 47) 
Exercise 
13 
22 
12 
Adenosine 
31 
14 
2 
p < 0.001 
Control Subjects (n = 53) 
Exercise 
48 
3 
2 
Adenosine 
p = NS 
49 
3 
(14 of 47 versus 1 of 53, p < 0.001). During adenosine 
infusion, however, chest pain occurred with similar fre-
quency in patients and normal control subjects (27 of 47 
versus 30 of 53, p = NS). 
Hemodynamic response to adenosine infusion. Eighty-
nine of the 100 subjects had a decrease in systolic blood 
pressure (mean decrease 13 ± 8 mm Hg). The lowest systolic 
blood pressure during adenosine infusion was 88 mm Hg in 
the group with coronary disease and 78 mm Hg in the control 
group. Thirty-four of the 100 subjects had an initial transient 
decrease in heart rate (mean decrease 5.6 ± 6.1 beats/min), 
but 99 had a subsequent increase in heart rate (mean increase 
24 ± 13 beats/min). 
Effects of adenosine on atrioventricular conduction. In 
general, adenosine infusion caused a prolongation of the PR 
interval of the ECG. The increase in PR duration tended to 
occur more often in patients; 72.3% of subjects with coro-
nary disease versus 43.4% of normal subjects experienced a 
prolongation of the PR interval above baseline measure-
ments. The increment was slight in both groups, however, 
with a mean change of 0.032 ± 0.018 s in patients and 0.038 
± 0.039 s change in control subjects. In four patients 
transient atrioventricular (A V) block developed. 
Adverse effects (Table 5). None of the 100 study subjects 
required premature termination of the adenosine thallium 
study or a decrease in infusion rate to < 140 JLg/kg per min 
because of adverse effects. Although side effects were fre-
quently described (94% of subjects), they were generally 
mild and never warranted therapy. The severity of the 
effects waxed and waned throughout the 6 min infusion 
period. The severity reported in Table 5 represents the peak 
intensity of the symptoms. 
Table 4. Chest Pain Response to Exercise and Adenosine Infusion 
None 
Mild 
Moderate 
Severe 
Patients 
33 
14 
o 
o 
Exercise 
Control 
Subjects 
52 
o 
o 
p < 0.001 
Adenosine 
Patients 
20 
8 
IO 
9 
p = NS 
Control 
Subjects 
23 
16 
8 
6 
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Table 5. Adenosine Adverse Effect Profile* in the 47 Patients and 
53 Control Subjects 
Mild Moderate Severe 
Shortness of breath (62%) 44 16 2 
Flushing (61%) 39 19 3 
Chest pain (57%) 24 18 15 
Throat tightness (32%) 17 13 2 
Nausea (24%) 16 7 I 
Headache (22%) 15 5 2 
Arm pain (9%) 5 4 0 
Light-headedness (7%) 6 0 
Leg pain (5%) 4 0 
AV blockt (4%) 0 3 I 
Dizziness (4%) 2 2 0 
Othert (13%) 8 4 
* Any symptom, 94% of patients; severe symptom, 20%. tin three patients 
transient asymptomatic second degree (Mobitz type I) atrioventricular block 
developed; one patient had a 5 s period of asymptomatic complete heart 
block. Wther symptoms, occurring in three or fewer subjects, were pares-
thesia, nasal stuffiness, anxiety, weakness, acid taste, dry mouth, jaw pain 
and warm sensation in chest. One patient reported severe anxiety. 
In four patients AV node block developed with adenosine 
infusion. One of these patients had high grade AV block 
(third degree heart block) that persisted for approximately 
5 s. In three patients Mobitz type I second degree A V block 
developed that persisted for 15 s, 30 sand 5 min, respec-
tively. Except for one of the patients with second degree A V 
block, all were receiving maintenance treatment with a 
calcium channel antagonist or a beta-adrenergic blocking 
agent, or both. All adverse effects noted in Table 5 and the 
periods of A V block just described resolved within 30 to 
45 s of termination of the adenosine infusion. 
Discussion 
Background. Since the early work of Gould et al. (11,12) 
demonstrated that thallium imaging after dipyridamole infu-
sion could be used to identify myocardial perfusion abnor-
malities in animals and humans, pharmacologic vasodilation 
has been used with increasing frequency in the diagnosis of 
coronary artery disease. Contrast material (13), papaverine 
(14) and intracoronary nitroglycerin (15) have also been used 
to produce coronary hyperemia. The mechanism for the 
inhomogeneous myocardial uptake of thallium-201 after 
vasodilation in patients with coronary artery disease is 
generally believed to reflect altered coronary flow reserve in 
vessels with stenosis relative to normal vessels. Alterna-
tively, various coronary steal mechanisms have been impli-
cated and may occur in certain subsets of patients (16-20). 
Adenosine has long been known to have potent cardio-
vascular effects, and the compound is believed to have a key 
role in the ability of the coronary vasculature to autoregulate 
blood flow. The myocardial mechanisms of adenosine's 
formation under normal and hypoxic conditions were re-
cently reviewed (21). Endogenously prod\lced or exoge-
nously administered adenosine acts on at least two sets of 
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receptors to effect dilation of coronary resistance vessels 
(22). The metabolism of adenosine occurs through active 
cellular uptake and enzymatic degradation, and the half-life 
of the exogenously infused nucleoside is approximately 10 s 
(9). Adenosine's vasoactivity is potentiated by agents such 
as dipyridamole, which block its uptake, and is attenuated 
by methylxanthines, which compete for the adenosine re-
ceptor. 
Wilson et al. (4), using 3F Doppler catheters, reported 
that an intravenous infusion of adenosine at 140 J,tg/kg per 
min augmented coronary blood flow to 4.4 ± 0.5 times 
baseline flow in the normal left coronary arteries of 10 
patients and achieved a maximal change in coronary flow in 
9 of them. This is comparable to the reported coronary flow 
response to intravenous administration of dipyridamole 
(13,14). 
Current study. The current study was undertaken to 
compare the diagnostic value of thallium-201 scintigraphy 
after intravenous infusion of adenosine with that of standard 
exercise thallium testing for evaluation of coronary artery 
disease. Adenosine thallium testing compared favorably 
with exercise thallium testing. There were no demonstrable 
differences between the two tests in their overall sensitivity, 
specificity, predictive value (positive and negative) and 
diagnostic accuracy in the evaluation of obstructive epicar-
dial disease. 
Sensitivity and specificity of thallium testing. The reported 
sensitivity of exercise thallium testing has varied consider-
ably in several recent series, from as low as 70% (23) to as 
high as 97% (24). This variability has been attributed to many 
factors including the use of planar versus tomographic 
thallium imaging, visual versus quantitative analysis of thal-
lium data, the level of exercise that patients are able to 
perform during treadmill testing (25) and the severity and 
extent of a patient's coronary disease. For the purposes of 
the present study, the overall sensitivity and specificity and 
the patient or technical variables that contribute to these test 
characteristics were less important than the comparability of 
the two thallium procedures. The patients in this study were 
not selected for enrollment on the basis of exercise tolerance 
(although all had to be capable of performing a treadmill test) 
or angiographic criteria (patients with left main coronary 
artery obstruction were excluded). The study subjects rep-
resented a fairly typical group referred for thallium testing at 
our institution. Within this "typical" population, adenosine 
performed as well as exercise thallium testing in the evalu-
ation of coronary disease. 
We have reported our sensitivity for the detection of 
coronary disease as the probability of producing a fixed or 
reversible defect on a thallium scintigram. The finding of 
myocardial scar by thallium imaging would not require a 
physiologic stimulus such as exercise or coronary vasodila-
tion, and our inclusion of patients with prior myocardial 
infarction in the study group could potentially skew the data 
toward improved disease detection. To investigate the abil-
ity of adenosine infusion to produce thallium scintigraphic 
lACC Vol. 17. No.6 
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abnormalities in patients without myocardial scar, we exam-
ined a group of 28 subjects with coronary disease but without 
evidence of transmural myocardial infarction by left ventric-
ulography. In this group, adenosine thallium and exercise 
thallium testing were again equally sensitive (79% and 75%, 
respectively) for the diagnosis of coronary disease. 
The specificity of exercise thallium testing is controver-
sial, and the influence of posttest referral bias has been 
emphasized (26). To avoid this bias in our data, specificity 
was calculated for the group with a low clinical probability of 
disease, excluding the subjects who underwent coronary 
angiography. In this group, the normalcy rate of both exer-
cise and adenosine thallium testing was 80%. This value is 
more likely to reflect the true specificity of each procedure, 
and again the two tests appear equally specific. 
ST segment response to adenosine infusion. Studies (27) 
with dipyridamole show that thallium uptake abnormalities 
without associated ST segment changes are common. In the 
present study, we also found this to be the case. During 
exercise treadmill testing, 12 (25%) of 47 patients with 
coronary disease developed an abnormal ECG response. 
However, with adenosine infusion, an abnormal ECGdevel-
oped in only 2 of 47. An abnormal shift of the ST segment 
also developed in 1 of the 53 control subjects during adeno-
sine infusion. It is apparent that the thallium abnormalities 
associated with infusion of adenosine develop without ECG 
evidence of ischemia. The diagnostic value of ECG abnor-
malities that develop during adenosine administration is 
limited. 
Chest pain response to adenosine infusion. Chest pain 
resulting from the drug's infusion was not useful in distin-
guishing the patient with coronary disease from the normal 
control subject. Twenty-seven (57%) of 47 patients and 30 
(57%) of 53 control subjects noted chest pain during the test. 
The lack of diagnostic value in the chest pain response to 
dipyridamole infusion was recently reported (28). It has been 
hypothesized that adenosine is the compound responsible 
for producing chest pain in patients with symptomatic ische-
mia (29), and our findings suggest that the interaction of 
adenosine and its receptor may be responsible for angina-
type symptoms even in the absence of myocardial ischemia. 
Adverse effects of adenosine infusion. In a previous study 
(30), the maximal tolerated dose of adenosine in most 
subjects was determined to be 140 p,g/kg per min. At larger 
doses, the dropout rate due to adverse effects is excessive. 
Consistent with this experience, we found that a very high 
percentage of our study group experienced subjective ad-
verse effects during the infusion. Ninety-four percent of 
subjects reported one or more symptoms during the adeno-
sine infusion, and 20% reported that at least one of these 
symptoms was severe. Although reported subjective symp-
toms were common, objective adverse responses were rare. 
The observed hemodynamic response was not unexpected; 
adenosine is a potent systemic vasodilator in all tissues 
except the kidney (3). In no case was the hypotension or 
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subsequent tachycardic response considered severe enough 
to warrant discontinuation of the infusion. 
Intravenous administration of adenosine as a bolus has 
been shown to produce A V block and has been used to 
interrupt paroxysmal supraventricular tachycardia (31). In 
four of the subjects in the present study, greater than first 
degree A V block developed, but in only one patient was it a 
high grade conduction delay (complete A V block). In one 
case of Mobitz type I second degree block, the abnormality 
persisted for 5 min of the 6 min infusion. In all other cases, 
including the episode of complete heart block, the conduc-
tion abnormality was short-lived and did not require prema-
ture termination of the infusion or treatment with aminophyl-
line. 
Three findings with regard to the tolerability of the 
reported adverse effects are important. First, the reported 
severity of adverse effects is related to the peak intensity of 
the symptom over the entire test period. The actual severity 
waxed and waned considerably throughout the infusion; 
consequently, no patient requested that the test be stopped. 
Second, all reported side effects abated within 30 to 45 s of 
termination of the infusion. Third, none of our patients had 
symptoms severe enough to warrant reversal of the drug 
effect with aminophylline. The very brief duration of drug-
related symptoms is consistent with the pharmacokinetics of 
adenosine in that the exogenously infused compound is 
rapidly metabolized by endothelial and red blood cells and 
has an estimated half-life of 10 s. 
Conclusions. Adenosine is known to have potent coro-
nary and systemic vasodilator properties. We have found 
that thallium-201 scintigraphy after intravenous infusion of 
adenosine has the same diagnostic value as that of standard 
exercise thallium testing for evaluation of coronary artery 
disease. The comparability of the two studies was evident in 
the group of patients without prior transmural myocardial 
infarction as well as in the overall group. The ECG and chest 
pain responses to adenosine were not diagnostically useful. 
Adverse effects of adenosine were frequent but clinically 
tolerable. Furthermore, because of the compound's very 
short half-life, all drug-related symptoms abated promptly on 
termination of the infusion. High grade A V node block 
occurred in only one patient and was of very brief duration. 
Adenosine thallium testing may be of particular value for 
evaluation of coronary disease in patients who cannot per-
form exercise tolerance tests. 
We thank Roger Blevins, PhD for help in the design of this study. 
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